Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation

English version České info

Background:
Typically observed at 2 y after surgical resection, late recurrence is a major challenge in the management of hepatocellular carcinoma (HCC). We aimed to develop a genomic predictor that can identify patients at high risk for late recurrence and assess its clinical implications.

Methods and Findings:
Systematic analysis of gene expression data from human liver undergoing hepatic injury and regeneration revealed a 233-gene signature that was significantly associated with late recurrence of HCC. Using this signature, we developed a prognostic predictor that can identify patients at high risk of late recurrence, and tested and validated the robustness of the predictor in patients (n = 396) who underwent surgery between 1990 and 2011 at four centers (210 recurrences during a median of 3.7 y of follow-up). In multivariate analysis, this signature was the strongest risk factor for late recurrence (hazard ratio, 2.2; 95% confidence interval, 1.3–3.7; p = 0.002). In contrast, our previously developed tumor-derived 65-gene risk score was significantly associated with early recurrence (p = 0.005) but not with late recurrence (p = 0.7). In multivariate analysis, the 65-gene risk score was the strongest risk factor for very early recurrence (<1 y after surgical resection) (hazard ratio, 1.7; 95% confidence interval, 1.1–2.6; p = 0.01). The potential significance of STAT3 activation in late recurrence was predicted by gene network analysis and validated later. We also developed and validated 4- and 20-gene predictors from the full 233-gene predictor. The main limitation of the study is that most of the patients in our study were hepatitis B virus–positive. Further investigations are needed to test our prediction models in patients with different etiologies of HCC, such as hepatitis C virus.

Conclusions:
Two independently developed predictors reflected well the differences between early and late recurrence of HCC at the molecular level and provided new biomarkers for risk stratification.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. PLoS Med 11(12): e32767. doi:10.1371/journal.pmed.1001770
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001770

Souhrn

Zdroje

1. International Agency for Research on Cancer (2013) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon (France): International Agency for Research on Cancer.

2. DavilaJA, MorganRO, ShaibY, McGlynnKA, El SeragHB (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127: 1372–1380.

3. El SeragHB, MasonAC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745–750.

4. El SeragHB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27–S34.

5. BruixJ, LlovetJM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519–524.

6. BruixJ, ShermanM (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–1236.

7. ImamuraH, MatsuyamaY, TanakaE, OhkuboT, HasegawaK, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200–207.

8. LlovetJM, FusterJ, BruixJ (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30: 1434–1440.

9. PoonRT, FanST, NgIO, LoCM, LiuCL, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500–507.

10. MantovaniA, AllavenaP, SicaA, BalkwillF (2008) Cancer-related inflammation. Nature 454: 436–444.

11. BoschFX, RibesJ, CleriesR, DiazM (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191–211.

12. El-SeragHB, RudolphKL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576.

13. SunB, KarinM (2013) Inflammation and liver tumorigenesis. Front Med 7: 242–254.

14. DvorakHF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659.

15. HaddowA (1972) Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res 16: 181–234.

16. IizukaN, OkaM, Yamada-OkabeH, NishidaM, MaedaY, et al. (2003) Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923–929.

17. LeeJS, ChuIS, HeoJ, CalvisiDF, SunZ, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.

18. WooHG, ParkES, CheonJH, KimJH, LeeJS, et al. (2008) Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 14: 2056–2064.

19. YeQH, QinLX, ForguesM, HeP, KimJW, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416–423.

20. HoshidaY, VillanuevaA, KobayashiM, PeixJ, ChiangDY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995–2004.

21. BudhuA, ForguesM, YeQH, JiaHL, HeP, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99–111.

22. WangSM, OoiLL, HuiKM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13: 6275–6283.

23. WangSM, OoiLL, HuiKM (2011) Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 17: 6040–6051.

24. BurchardJ, ZhangC, LiuAM, PoonRT, LeeNP, et al. (2010) microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 6: 402.

25. RoesslerS, LongEL, BudhuA, ChenY, ZhaoX, et al. (2011) Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142: 957–966.

26. de JongeJ, KurianS, ShakedA, ReddyKR, HancockW, et al. (2009) Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts. Am J Transplant 9: 758–772.

27. BolstadBM, IrizarryRA, AstrandM, SpeedTP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185–193.

28. SimonR, LamA, LiM-C, NganM, MenenzesS, et al. (2007) Analysis of gene expression data using BRB-Array Tools. Cancer Inform 3: 11–17.

29. WrightGW, SimonRM (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448–2455.

30. RadmacherMD, McShaneLM, SimonR (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505–511.

31. TibshiraniR, HastieT, NarasimhanB, ChuG (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567–6572.

32. CoxDR (1972) Regression models with life tables. J R Stat Soc 34: 187–220.

33. KramerA, GreenJ, PollardJJr, TugendreichS (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30: 523–530.

34. KimSM, LeemSH, ChuIS, ParkYY, KimSC, et al. (2011) Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55: 1443–1452.

35. ShahSA, GreigPD, GallingerS, CattralMS, DixonE, et al. (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202: 275–283.

36. RegimbeauJM, AbdallaEK, VautheyJN, LauwersGY, DurandF, et al. (2004) Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 85: 36–41.

37. ShimadaM, TakenakaK, GionT, FujiwaraY, KajiyamaK, et al. (1996) Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111: 720–726.

38. ManK, LoCM, XiaoJW, NgKT, SunBS, et al. (2008) The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 247: 1049–1057.

39. ShiJH, HuitfeldtHS, SuoZH, LinePD (2011) Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 17: 866–874.

40. van der BiltJD, KranenburgO, NijkampMW, SmakmanN, VeenendaalLM, et al. (2005) Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 42: 165–175.

41. van der BiltJD, KranenburgO, BorrenA, vanHR, Borel RinkesIH (2008) Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 15: 1392–1398.

42. ManK, NgKT, LoCM, HoJW, SunBS, et al. (2007) Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases—activation of cell invasion and migration pathways. Liver Transpl 13: 1669–1677.

43. WangH, HuangZQ, XiaL, FengQ, Erdjument-BromageH, et al. (2001) Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293: 853–857.

44. PoserSW, ParkDM, Androutsellis-TheotokisA (2013) The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth. Front Physiol 4: 273.

45. HeG, YuGY, TemkinV, OgataH, KuntzenC, et al. (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17: 286–297.

46. YuH, PardollD, JoveR (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798–809.

47. NauglerWE, SakuraiT, KimS, MaedaS, KimK, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121–124.

48. RadaevaS, SunR, PanHN, HongF, GaoB (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332–1342.

49. SaxenaNK, SharmaD, DingX, LinS, MarraF, et al. (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497–2507.

50. LiuJ, SatoC, CerlettiM, WagersA (2010) Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 92: 367–409.

51. EzzeldinM, Borrego-DiazE, TahaM, EsfandyariT, WiseAL, et al. (2014) RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC). Mol Oncol 8: 1043–1053.

52. DingX, WangK, WangH, ZhangG, LiuY, et al. (2012) High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg 16: 828–836.

53. YangSF, YehYT, WangSN, HungSC, ChenWT, et al. (2008) SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology 40: 558–563.

54. Al-HussainiH, SubramanyamD, ReedijkM, SridharSS (2011) Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 10: 9–15.

55. SansoneP, BrombergJ (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30: 1005–1014.